PREVNAR + C295 ISS VACCINE FORMULATION IN INFANT BABOONS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本实验的目的是首次测试商用肺炎球菌7价疫苗制剂(Prevnar)单独或与免疫刺激DNA序列(C295 ISS和C295-PMXB)结合在一起对婴儿狒狒的免疫原性。Prevnar疫苗与C295 ISS或C295-PMXB联合在成年狒狒(952-PC-0)上进行了试验，证明是安全的。这项研究将有助于确定Prevnar与C295 ISS或C295-PMXB疫苗配方联合使用是否能提高婴儿对肺炎球菌多糖抗原的抗体反应，这将有助于开发一种新的婴儿肺炎球菌疫苗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to test for the first time in infant baboons the immunogenicity of a commercial pneumococcal 7-valent vaccine formulation (PREVNAR¿) alone, or in combination immunostimulatory DNA sequences (C295 ISS and C295-PMXB). PREVNAR¿ vaccine in combination with C295 ISS or C295-PMXB was tested in adult baboons (952-PC-0) and was shown to be safe. This study will help decide if PREVNAR¿ combined with C295 ISS or C295-PMXB vaccine formulation can elicit improved antibody responses in infant baboons to pneumococcal polysaccharide antigens, which will assist in the development of a new pneumococcal vaccine for human infants.